AGC Biologics, a global contract development and manufacturing organization (CDMO), has announced the expansion of its cell therapy manufacturing capabilities in Asia. The move reflects the company’s continued commitment to supporting advanced therapy development and manufacturing in one of the world’s fastest-growing biotech regions.

Strategic Growth in Advanced Therapies

This expansion includes investments in:

• Enhanced GMP cell therapy production suites

• Process development and scale-up capabilities for autologous and allogeneic therapies

• Regulatory support infrastructure tailored for Asia-Pacific clients

AGC Biologics aims to meet growing demand from biotech and pharmaceutical companies pursuing regenerative medicine and cell-based immunotherapies.

Supporting the Asia-Pacific Biotech Ecosystem

The company's expanded footprint will:

• Provide end-to-end support from clinical to commercial manufacturing

• Strengthen local partnerships with developers in Japan, Korea, and Southeast Asia

• Align with regional regulatory requirements to accelerate time to market

Executive Commentary

A representative from AGC Biologics stated:
“Asia is a key region for innovation in cell and gene therapy. Our expanded capabilities will provide essential resources for emerging and established developers alike.”

👉 Read the full analysis at- AGC Biologics Grows Cell Therapy Presence in Asia

👉 Subscribe us IT Business Today

https://itbusinesstoday.com/